{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:57:35Z","timestamp":1793332655796,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunotherapy for ovarian cancer is an area of intense investigation since the majority of women with relapsed disease develop resistance to conventional cytotoxic therapy. The paucity of safe and validated target antigens has limited the development of clinically relevant antibody-based immunotherapeutics for this disease. Although MUC16 expression is almost universal in High Grade Serous Ovarian Cancers, engagement of the shed circulating MUC16 antigen (CA-125) presents a theoretical risk of systemic activation and toxicity. We designed and evaluated a series of bispecific tandem single-chain variable fragments specific to the retained portion of human MUC16 ectodomain (MUC16<jats:sup>ecto<\/jats:sup>) and human CD3. These MUC16<jats:sup>ecto<\/jats:sup>- BiTEDs retain binding in the presence of soluble MUC16 (CA-125) and show cytotoxicity against a panel of ovarian cancer cells <jats:italic>in vitro<\/jats:italic>. MUC16<jats:sup>ecto<\/jats:sup>- BiTEDs delay tumor progression <jats:italic>in vivo<\/jats:italic> and significantly prolong survival in a xenograft model of ovarian peritoneal carcinomatosis. This effect was significantly enhanced by antiangiogenic (anti-VEGF) therapy and immune checkpoint inhibition (anti-PD1). However, the combination of BiTEDs with anti-VEGF was superior to combination with anti-PD1, based on findings of decreased peritoneal tumor burden and ascites with the former. This study shows the feasibility and efficacy of MUC16<jats:sup>ecto<\/jats:sup>- specific BiTEDs and provides a basis for the combination with anti-VEGF therapy for ovarian cancer.<\/jats:p>","DOI":"10.3389\/fimmu.2021.663379","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T08:21:35Z","timestamp":1618388495000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Bispecific T-Cell Engaging Antibodies Against MUC16 Demonstrate Efficacy Against Ovarian Cancer in Monotherapy and in Combination With PD-1 and VEGF Inhibition"],"prefix":"10.3389","volume":"12","author":[{"given":"Oladapo O.","family":"Yeku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thapi Dharma","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Laster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Kononenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence J.","family":"Purdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J.","family":"Brentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.01.021","article-title":"Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer","volume":"132","author":"Mehta","year":"2014","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/1097-0215(20000701)87:1<79::AID-IJC12>3.0.CO;2-L","article-title":"Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial","volume":"87","author":"Sabbatini","year":"2000","journal-title":"Int J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0646","article-title":"FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer","volume":"14","author":"Moore","year":"2018","journal-title":"Future Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.08.005","article-title":"T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics","volume":"182","author":"Wu","year":"2018","journal-title":"Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22524","article-title":"How do CARs work?: Early insights from recent clinical studies targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp Cell Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3349","article-title":"Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1","volume":"33","author":"Dao","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1326437","DOI":"10.1080\/2162402X.2017.1326437","article-title":"An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors","volume":"6","author":"Gohil","year":"2017","journal-title":"Oncoimmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-0042","article-title":"Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens","volume":"11","author":"Friedrich","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.5034","article-title":"Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Hummel","year":"2019","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402517","article-title":"B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity","volume":"194","author":"Wu","year":"2015","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"B21","article-title":"The CA 125 gene: an extracellular superstructure dominated by repeat sequences","volume":"22","author":"O\u2019Brien","year":"2001","journal-title":"Tumour Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.08.014","article-title":"Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer","volume":"200","author":"Bellone","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0b013e3181dbfcd2","article-title":"Novel monoclonal antibodies against the proximal (carboxy-terminal) portions of MUC16","volume":"18","author":"Dharma Rao","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B26","article-title":"Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin","volume":"55","author":"Dhingra","year":"1995","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034","article-title":"MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors","volume":"43","author":"Brischwein","year":"2006","journal-title":"Mol Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.7b00305","article-title":"Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth","volume":"12","author":"Rao","year":"2017","journal-title":"ACS Chem Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e0126633","DOI":"10.1371\/journal.pone.0126633","article-title":"Expression of the Carboxy-Terminal Portion of MUC16\/CA125 Induces Transformation and Tumor Invasion","volume":"10","author":"Rao","year":"2015","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10250","article-title":"Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene","volume":"98","author":"Yin","year":"2002","journal-title":"Int J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1159\/000484109","article-title":"Membranous and Cytoplasmic Expression of PD-L1 in Ovarian Cancer Cells","volume":"43","author":"Qu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.101","article-title":"IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer","volume":"112","author":"Abiko","year":"2015","journal-title":"Br J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)65669-6","article-title":"Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization","volume":"153","author":"Mesiano","year":"1998","journal-title":"Am J Pathol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/(sici)1097-0142(19970701)80:1<98::aid-cncr13>3.0.co;2-a","article-title":"Vascular endothelial growth factor expression in early stage ovarian carcinoma","volume":"80","author":"Paley","year":"1997","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2015.08.017","article-title":"Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives","volume":"97","author":"Colombo","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/jog.14112","article-title":"The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer","volume":"45","author":"Shimizu","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-695X.2000.tb01437.x","article-title":"Impairment of T-cell functions with the progressive ascitic growth of a transplantable T-cell lymphoma of spontaneous origin","volume":"27","author":"Shanker","year":"2000","journal-title":"FEMS Immunol Med Microbiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12935-015-0263-4","article-title":"High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation","volume":"15","author":"Bourgeois","year":"2015","journal-title":"Cancer Cell Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.07.025","article-title":"Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient","volume":"170","author":"Jimenez-Sanchez","year":"2017","journal-title":"Cell"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.2948","article-title":"Inhibition of HIF-1alpha by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7534","article-title":"A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer","volume":"11","author":"Crawford","year":"2019","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0360","article-title":"Anti-VEGF Treatment Enhances CD8(+) T-cell Antitumor Activity by Amplifying Hypoxia","volume":"8","author":"de Almeida","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e989776","DOI":"10.4161\/2162402X.2014.989776","article-title":"Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody","volume":"4","author":"Ahmed","year":"2015","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.663379\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T08:21:38Z","timestamp":1618388498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.663379\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2021.663379"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.663379","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"article-number":"663379"}}